Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aihengping (bupivacaine liposome)
- Development stage
- Approved
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
Aihengping (HR18034) is an extended-release liposomal formulation of the amide-type local anesthetic bupivacaine, developed by Jiangsu Hengrui Medicine. It utilizes multivesicular liposome (MVL) technology to encapsulate bupivacaine, providing a sustained release that extends the duration of analgesia for up to 72 hours post-administration. Bupivacaine works by reversibly binding to and blocking voltage-gated sodium channels on the internal surface of nerve cell membranes. This blockade prevents the influx of sodium ions, thereby inhibiting the depolarization of the nerve membrane and the subsequent conduction of pain impulses. Aihengping was approved by the NMPA in China in 2024 for local infiltration analgesia to manage postoperative pain, specifically following bunionectomy, and is being investigated for broader applications in regional nerve blocks, such as paravertebral blocks for thoracic surgery.
- Brand names
- Aihengping
- Other names
- liposomal bupivacainebupivacaine multivesicular liposome
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)SCN5A (Sodium channel protein type 5 subunit alpha)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Aihengping (bupivacaine liposome).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aihengping (bupivacaine liposome).